Citations

Showing 10 of 108162 citations.

Effectiveness and Safety of EUS Rendezvous After Failed Biliary Cannulation With ERCP
Klair, Jagpal S. , Zafar, Yousaf , Ashat, Munish , Bomman, Shivanand , Jayaraj, Mahendran , Law, Joanna K. , Larsen, Michael , Singh, Dhruv P. , Rustagi, Tarun , Irani, Shayan , Ross, Andrew , Kozarek, Richard A. , Krishnamoorthi, Rajesh , Murali, Arvind R.

Mayo Clinic

Journal of Clinical Gastroenterology | April 9, 2021 | Volume: 57 | Issue: 2 | Pages: 211-217

10.1097/mcg.0000000000001543 | PMID 34009843 Get It

Background: Endoscopic ultrasound–guided rendezvous (EUS-RV) endoscopic retrograde cholangiopancreatography (ERCP) is an alternative to interventional radiology–guided rendezvous ERCP in patients who failed biliary cannulation with conventional ERCP. However, there is significant variation in reported rates of success and adverse events associated with EUS-RV-assisted ERCP. We performed a systematic review and a proportion meta-analysis to reliably assess the effectiveness and safety of the EUS-RV-assisted ERCP. Materials and Methods: We conducted a comprehensive search of multiple electronic databases and conference proceedings (from inception through August 2020) to identify studies reporting EUS-RV-assisted ERCP in patients who failed biliary cannulation with conventional ERCP techniques. Using the random-effects model described by DerSimonian and Laird, we calculated the pooled rates of technical success, clinical success, and adverse events of EUS-RV-assisted ERCP. Results: Twelve studies reporting a total of 342 patients were included in the meta-analysis. The pooled rate of technical success (12 studies reporting a total of 342 patients) was 86.1% [95% confidence interval (CI): 78.4-91.3]. The pooled rate of clinical success (4 studies reporting a total of 94 patients) was 80.8% (95% CI: 64.1-90.8). The pooled rate of overall adverse events (12 studies; 42 events in 342 patients) was 14% (95% CI: 10.5-18.4). Low to moderate heterogeneity was noted in the analyses. Conclusions: EUS-RV-assisted ERCP appears to be effective and safe in patients who failed biliary cannulation with conventional ERCP. Given the risk of adverse events, it should be performed in centers with expertise in therapeutic endoscopic ultrasound.
The continuum of informed consent models in transgender health
Amand, Colton M St., Rider, G. Nic , Ashley, Florence , St Amand, Colton M, Rider, G. Nic , Amand, Colt St.

Mayo Clinic

Family Practice | April 9, 2021 | Volume: 38 | Issue: 4 | Pages: 543-544

10.1093/fampra/cmab047 | PMID 34133715 Get It

A novel method for sensor-based quantification of single/multicellular force dynamics and stiffening in 3D matrices
Emon, Bashar , Li, Zhengwei , Joy, Md Saddam Hossain , Doha, Umnia , Kosari, Farhad , Saif, M. Taher A. , Joy, Md Saddam H , Saif, Taher A.

Mayo Clinic

Science Advances | April 9, 2021 | Volume: 7 | Issue: 15 | Pages: No page available

10.1126/sciadv.abf2629 | PMID 33837084 Get It

A nano-resolution PDMS sensor simultaneously measures cell force and matrix stiffening dynamics in 3D.
Integrative Pan-cancer Analysis of MEK1 Aberrations and the Potential Clinical Implications
Li, Juanni , Huang, Jinzhou , Cai, Yuan, Zhou, Zhiyang , Bi, Peng , Cai, Yuan, Xu, Zhijie , Yan, Yuanliang

Mayo Clinic

No container title available | April 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-392196/v1 Get It

Abstract Background: Alterations of mitogen-activated protein kinase kinase 1 (MEK1) are commonly associated with tumorigenesis, and MEK1 is thought to be a suitable targeted therapy for various cancers. However, abnormal MEK1 alterations and their relevant clinical implications are unknown. Our research comprehensively analyzed the MEK1 alteration spectrum and provided novel insight for targeted therapies. Methods: There were 7694 samples covering 32 types of cancer from The Cancer Genome Atlas (TCGA) database. They were used to conduct an integrative analysis of MEK1 expression, alterations, functional impacts and clinical significance. Results: There was a dramatic difference in the alteration frequency and distribution and clinical implications in 32 types of cancer from the TCGA. Skin cutaneous melanoma (SKCM) has the most alterations and has therapeutic targets located in the protein kinase domain, and the growing expression of SKCM is positively related to patient prognosis. MEK1 expression in lung adenocarcinoma (LUAD), kidney renal papillary cell carcinoma (KIRP), esophageal carcinoma (ESCA) and liver hepatocellular carcinoma (LIHC) is decreased, which is associated with better prognosis, while MEK1 expression in thymoma (THYM), stomach adenocarcinoma (STAD), kidney renal clear cell carcinoma (KIRC), testicular germ cell tumors (TGCTs) and head and neck squamous cell carcinoma (HNSC) is increased, which is associated with better prognosis. Mesothelioma (MESO) has the second highest alterations but has no therapy targets. Conclusion: This study provided a great and detailed interpretation of MEK1 expression, alterations and clinical implications in 32 types of cancer and reminded us to fill the gap in MEK1 research from a new perspective. Keywords: MEK1, gene mutation, gene alteration, outcome, pan-cancer
Most Patients with COVID-19 Are Euthyroid
Motahari, Hooman, Maraka, Spyridoula

Mayo Clinic

Clinical Thyroidology | April 9, 2021 | Volume: 33 | Issue: 4 | Pages: 171-173

10.1089/ct.2021;33.171-173 Get It

A New Era in Antigen-Specific Immunotherapy: The Promise of Nucleoside-Modified mRNA Vaccines for Autoimmune Thyroid Disease
Banga, J. Paul, Stan, Marius N.

Mayo Clinic

Clinical Thyroidology | April 9, 2021 | Volume: 33 | Issue: 4 | Pages: 154-156

10.1089/ct.2021;33.154-156 Get It

Urticarial vasculitis: A Complication of SMZ‐TMP therapy
Bhasin, Arveen , Sluzevich, Jason C. , Bhasin, Arveen K , Sluzevich, Jason C

Mayo Clinic

Clinical Case Reports | April 9, 2021 | Volume: 9 | Issue: 5 | Pages: No page available

10.1002/ccr3.3872 | PMID 34084476 Get It

AbstractRecognize that delayed hypersensitivity reactions to sulfonamides may present as urticated plaques with hyperpigmentation and purpura for which a diagnosis of urticarial vasculitis should be considered.
CARDIOVASCULAR RISK PROFILE IN YOUNG PATIENTS WITH EPILEPSY
Szczurkowska, Patrycja J., Wolf, Jacek , Pilarska, Ewa, Hoffmann, Michał , Chrostowska, Marzena , Polonis, Katarzyna , Becari, Christiane , Mazurkiewicz‐Bełdzińska, Maria , Narkiewicz, Krzysztof

Mayo Clinic

Journal of Hypertension | April 9, 2021 | Volume: 39 | Issue: Supplement 1 | Pages: e156

10.1097/01.hjh.0000746092.16662.b9 Get It

Abstract Objective: The risk of premature deaths in patients with epilepsy (approx. 50 mln. patients worldwide) is about 2–3 times higher as compared to general population. This phenomenon is mainly explained by cardiovascular causes as well as sudden unexpected deaths in epilepsy (SUDEP). Epilepsy is associated with sympathetic overdrive and renin-angiotensin-system abnormalities all of which may be implicated in organ damage (both directly and indirectly via high blood pressure; BP). In our study, we aimed at the evaluation of several cardiovascular risk factors and organ damage in patients with epilepsy; its’ relation to disease control and comorbid hypertension. Design and method: A total of 48 patients and matched controls were included in the study. Anthropometry, biochemical assessment, office and ambulatory blood pressure, structural and/ or functional vascular changes were recorded. One-way ANOVA and ANCOVA were employed (mean ± SE). Results: Patients were comparable in terms of age and BMI. Hypertensives were aware of high BP in 50% of cases. Study subgroups were comparable in terms of heart rate, serum uric acid, triglicerides, HDL, glucose, serum creatinine and eGFR, serum potassium (P = NS for all comparisons). Total cholesterol was the lowest in well-controlled epileptic patients which was followed by refractory disease and epilepsy with comorbid hypertension (167.6 ± 6.7 vs. 196.9 ± 7.4 vs. 223.5 ± 8.9; respectively). Patients with refractory epilepsy had comparable serum LDL and PWV to hypertensive well-controlled epileptics; both contrasted with values recorded in patients with well-controlled epilepsy who were free of hypertension (LDL: 121.7 ± 6.8 vs. 140.9 ± 8.2 vs. 99.2 ± 6.1; respectively, and PWV: 6.4 ± 0.24 vs. 6.8 ± 0.30 vs. 5.5 ± 0.22; respectively). Reported differences were valid after adjustment for age and BMI. Conclusions: Except for BP values, patients with refractory epilepsy who are free of hypertension have similar CV risk profile to patients with high BP. These findings along with underdiagnosed hypertension may explain higher CV mortality and morbidity documented in epilepsy.